 |
424 Diseases |  |
809 Trials |
|
809 Trials |  |
14393 News |  |
| «12...100101102103104105106107108109110...235236» |
- | mitomycin / Generic mfg., cisplatin / Generic mfg., epirubicin / Generic mfg.
Journal: Use of chemotherapy to treat hepatocellular carcinoma. (Pubmed Central) - Mar 16, 2022
Moreover, locoregional chemotherapy can be achieved with TACE and HAIC (possibly involving FOLFOX, DOX, mitomycin C, cisplatin, epirubicin, etc.)...Hence, this review summarizes large-scale trials and studies examining the development and innovative use of chemotherapeutic agents. Mounting clinical evidence warrants an exploration of the efficacy of chemotherapy.
- | leucovorin calcium / Generic mfg., sulphadiazine / Generic mfg., pyrimethamine / Generic mfg.
Journal: Delta-aminolevulinate dehydratase enzyme activity and the oxidative profile of pregnant women being treated for acute toxoplasmosis. (Pubmed Central) - Mar 16, 2022
Pregnant women treated for this acute infection showed increased damage markers, as well as a significant increase in the antioxidant system, including the activity of the δ-ALA-D enzyme. Given this evidence, it is suggested that these changes occur as a form of compensation, with a possible contribution from drug therapy.
- ||| Braftovi (encorafenib) / Pfizer, Mektovi (binimetinib) / Pfizer
Trial completion date, Metastases: BEACON CRC: Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab With a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 16, 2022
P3, N=702, Active, not recruiting, Sponsor: Pfizer
Given this evidence, it is suggested that these changes occur as a form of compensation, with a possible contribution from drug therapy. Trial completion date: May 2022 --> Sep 2022
- | Cyramza (ramucirumab) / Eli Lilly
Journal: Ramucirumab plus triplet chemotherapy as an alternative salvage treatment for patients with metastatic colorectal cancer. (Pubmed Central) - Mar 16, 2022
Trial completion date: May 2022 --> Sep 2022 Ramucirumab plus triplet chemotherapy may be an alternative regimen in patients with mCRC, particularly as a later-line treatment modality.
- | oxaliplatin / Generic mfg., albumin-bound paclitaxel / Generic mfg., gemcitabine / Generic mfg.
Enrollment open, Combination therapy, Metastases: TCOG T5221: A Phase II Randomized Study of Gemcitabine and Nab-paclitaxel in Combination With S- 1/LV (GASL) or Oxaliplatin (GAP) as First-line Treatment for Metastatic Pancreatic Cancer (clinicaltrials.gov) - Mar 16, 2022
P2, N=86, Recruiting, Sponsor: National Health Research Institutes, Taiwan
Ramucirumab plus triplet chemotherapy may be an alternative regimen in patients with mCRC, particularly as a later-line treatment modality. Not yet recruiting --> Recruiting
- | methotrexate / Generic mfg.
Preclinical, Journal: Translationally relevant mouse model of early life cancer and chemotherapy exposure results in brain and small intestine cytokine responses: a potential link to cognitive deficits. (Pubmed Central) - Mar 15, 2022
To address how early life cancer chemotherapy leads to cognitive deficits, we developed a translationally relevant mouse model of leukemia survival that exposed mice to leukemic cells and chemotherapeutic drugs (vincristine and MTX, with leucovorin rescue) in early life...Inflammation in the small intestine was correlated with prefrontal cortical proinflammatory and synaptic gene expression changes, as well as to executive function deficits. Collectively, these data indicate that the current protocol results in a robust mouse model in which to study cognitive deficits in leukemia survivors, and suggest that small intestine inflammation may represent a novel contributor to adverse CNS consequences of early life chemotherapy.
- || 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Clinical, Journal: Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. (Pubmed Central) - Mar 15, 2022
P2
This secondary analysis of a randomized clinical trial showed that CRT followed by chemotherapy resulted in higher pathological complete response without compromising disease-free survival, toxicity, QoL, or stool incontinence and is thus proposed as the preferred total neoadjuvant therapy sequence if organ preservation is a priority. ClinicalTrials.gov identifier: NCT02363374.
- || irinotecan / Generic mfg.
Review, Journal: Borderline Resectable and Locally Advanced Pancreatic Cancers: A Review of Definitions, Diagnostics, Strategies for Treatment, and Future Directions. (Pubmed Central) - Mar 15, 2022
Surgery on these tumors remains a significantly challenging task for pancreatic surgeons. More studies are needed to determine the best agents to be used in the neoadjuvant and adjuvant settings, biologic markers for prognostic and operative predictions, and validation of previously published retrospective results.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Contribution of neoadjuvant chemotherapy in rectal cancer (Pubmed Central) - Mar 15, 2022
The chemotherapy efficacy on the rectal tumor as well as the difficulties to administer adjuvant chemotherapy after proctectomy has led to the development of treatment regimens with neoadjuvant chemotherapy. Two phase III studies evaluating induction chemotherapy with FOLFIRINOX followed by chemoradiotherapy for one and short radiotherapy followed by consolidation chemotherapy for the other are positive for their main objective and constitute new therapeutic standards.
- | leucovorin calcium / Generic mfg.
Journal: Efficacy and Safety of Ferrous Bisglycinate and Folinic Acid in the Control of Iron Deficiency in Pregnant Women: A Randomized, Controlled Trial. (Pubmed Central) - Mar 15, 2022
The test intervention was also associated with significantly fewer reports of nausea, abdominal pain, bloating, constipation, or metallic taste (p < 0.001). In conclusion, ferrous bisglycinate with folinic acid as a multivitamin nutraceutical format is comparable to standard ferrous fumarate for the clinical management of iron deficiency during pregnancy, with comparatively better absorption, tolerability, and efficacy and with a lower elemental iron dosage.
- || Avastin (bevacizumab) / Roche
P2 data, Journal: mFOLFOXIRI with or without bevacizumab for conversion therapy of RAS/BRAF/PIK3CA mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trial. (Pubmed Central) - Mar 15, 2022
We observed that the combination of mFOLFOXIRI and bevacizumab increased the rate of clinical NED and showed a trend toward improved survival compared with mFOLFOXIRI alone. This could represent a conversion therapy option for fit patients with initially unresectable RAS/BRAF/PIK3CA mutant CRLMs.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Is FOLFOX-HAIC superior to transarterial chemoembolization in treating large hepatocellular carcinoma? (Pubmed Central) - Mar 15, 2022
This could represent a conversion therapy option for fit patients with initially unresectable RAS/BRAF/PIK3CA mutant CRLMs. No abstract available
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Journal: Conversion surgery for undifferentiated carcinoma with osteoclast-like giant cells of the pancreas: a case report. (Pubmed Central) - Mar 15, 2022
We experienced a case undergoing conversion surgery for unresectable UCOGC, which resulted in R0 resection. FOLFIRINOX could be a possible regimen to achieve conversion surgery for UCOGC.
- Avastin (bevacizumab) / Roche
FOLFOX-bevacizumab chemotherapy in patients with progressive metastatic neuroendocrine tumors () - Mar 14, 2022 - Abstract #ENETS2022ENETS_302;
FOLFIRINOX could be a possible regimen to achieve conversion surgery for UCOGC. The FOLFOX-bevacizumab combination has promising efficacy in patients with progressive metastatic NETs, notably in those with G3 NETs.
- cisplatin / Generic mfg., temozolomide / Generic mfg.
Trends in chemotherapy use in neuroendocrine neoplasms: One step beyond guidelines () - Mar 14, 2022 - Abstract #ENETS2022ENETS_300;
The incorporation of ADK-like regimens and CAPTEM has been the main trend in CT clinical practice in recent years. Comparative clinical trials between CT regimens should be a priority in the coming years.
- irinotecan / Generic mfg.
A multicentric randomized phase II trial of CAPTEM (CT) or Folfiri (F) as second-line therapy in neuroendocrine carcinomas (NEC) and exploratory analysis of predictive role of PET imaging and biological markers (SENECA Study) () - Mar 14, 2022 - Abstract #ENETS2022ENETS_293;
Survival in NEC pts remains poor. Despite the study didn't meet the primary end–point FOLFIRI seems to have an impact on NEC disease while CAPTEM role is limited to pts with Ki67 ≤ 55%.
- ifosfamide / Generic mfg., cisplatin / Generic mfg., temozolomide / Generic mfg.
Grade 3 neuroendocrine neoplasms – Real life experience and prognostic biomarkers () - Mar 14, 2022 - Abstract #ENETS2022ENETS_246;
High SII and Ki67>50% can negatively predict overall survival and could be low-cost tool to individualize treatment in G3 NEN. More studies are needed.
- etoposide IV / Generic mfg., paclitaxel / Generic mfg.
Etoposide-based rechallenge and second/third line treatments in patients with metastatic neuroendocrine carcinoma: Results from the multicenter RBNEC study of the Groupe d'Etude des Tumeurs Endocrines (GTE) and the ENDOCAN-RENATEN network () - Mar 14, 2022 - Abstract #ENETS2022ENETS_242;
EBR is a second-line option in case of a PFI > 4 months. Rb status did not provide prognostic or predictive information on the best SL option in our cohort.
- || Keytruda (pembrolizumab) / Merck (MSD)
Clinical, P2 data, Journal: Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial. (Pubmed Central) - Mar 12, 2022
P2
Pembrolizumab added to chemoradiotherapy as part of total neoadjuvant therapy was suggested to be safe; however, the NAR score difference does not support further study. ClinicalTrials.gov Identifier: NCT02921256.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Clinical, Journal: Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. (Pubmed Central) - Mar 11, 2022
The benefit of adjuvant chemotherapy after resection of pancreatic cancer following neoadjuvant combination treatment with folinic acid, fluorouracil, irinotecan, and oxaliplatin (FOLFIRINOX) is unclear...Overall, 343 patients (66.0%) received adjuvant chemotherapy, of whom 68 (19.8%) received FOLFIRINOX, 201 (58.6%) received gemcitabine-based chemotherapy, 14 (4.1%) received capecitabine, 45 (13.1%) received a combination or other agents, and 15 (4.4%) received an unknown type of adjuvant chemotherapy...These results suggest that adjuvant chemotherapy after neoadjuvant FOLFIRINOX and resection of pancreatic cancer was associated with improved survival only in patients with pathology-proven node-positive disease. Future randomized studies should be conducted to confirm this finding.
- || Hepacid (pegargiminase) / Polaris Pharma
Clinical, P2 data, Journal: Assessment of pegylated arginine deiminase and modified FOLFOX6 in patients with advanced hepatocellular carcinoma: Results of an international, single-arm, phase 2 study. (Pubmed Central) - Mar 11, 2022
Concurrent mFOLFOX6 plus ADI-PEG 20 exhibited limited antitumor activity in patients with treatment-refractory HCC. The study was terminated early, and no further evaluation of the combination will be pursued.
- || Avastin (bevacizumab) / Roche
Clinical, PK/PD data, Journal: Integration of DNA sequencing with population pharmacokinetics to improve the prediction of irinotecan exposure in cancer patients. (Pubmed Central) - Mar 11, 2022
This new model significantly reduced the interindividual variability in the clearance of irinotecan and SN-38. New genetic factors of variability in clearance have been identified.
- ||| Avastin (bevacizumab) / Roche
Clinical, P3 data, Journal: Phase III randomized trial comparing systemic versus intra-arterial oxaliplatin, combined with LV5FU2 +/- irinotecan and a targeted therapy, in the first-line treatment of metastatic colorectal cancer restricted to the liver (OSCAR): PRODIGE 49. (Pubmed Central) - Mar 11, 2022
P3
New genetic factors of variability in clearance have been identified. This study is planned to include 348 patients to demonstrate the superiority of HAI-ox over systemic oxaliplatin in first-line CRCLM treatment (NCT02885753).
- | leucovorin calcium / Generic mfg., tegafur/uracil / Generic mfg.
Observational data, Journal: Prospective observational study of the efficacy of oral uracil and tegafur plus leucovorin for stage II colon cancer with risk factors for recurrence using propensity score matching (JFMC46-1201). (Pubmed Central) - Mar 11, 2022
This study is planned to include 348 patients to demonstrate the superiority of HAI-ox over systemic oxaliplatin in first-line CRCLM treatment (NCT02885753). Adjuvant chemotherapy with UFT/LV showed a significant survival benefit over surgery alone in patients with high-risk stage II CC characterized by at least one of the following conditions: T4 disease, perforation/penetration, poorly differentiated adenocarcinoma/mucinous carcinoma, or < 12 dissected lymph nodes.
- | Abraxane (albumin-bound paclitaxel) / BMS, Otsuka
Preclinical, Journal: Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model. (Pubmed Central) - Mar 11, 2022
Adjuvant chemotherapy with UFT/LV showed a significant survival benefit over surgery alone in patients with high-risk stage II CC characterized by at least one of the following conditions: T4 disease, perforation/penetration, poorly differentiated adenocarcinoma/mucinous carcinoma, or < 12 dissected lymph nodes. We demonstrate the utility and feasibility of clinically relevant mFOLFIRINOX and gemcitabine/nab-paclitaxel in preclinical models of pancreatic cancer.
- || irinotecan / Generic mfg.
Biomarker, Clinical, Retrospective data, Review, Journal: Neoadjuvant treatment of pancreatic carcinosarcoma: a case report and review of literature. (Pubmed Central) - Mar 11, 2022
Here we report a case of pancreatic carcinosarcoma treated with neoadjuvant FOLFIRINOX followed by chemoradiation with pathological partial response. Modern treatment approaches for pancreatic ductal adenocarcinoma (PDAC) could be applied to this rare pathology.
- | Avastin (bevacizumab) / Roche
Journal, PD(L)-1 Biomarker, IO biomarker: Intratumoral density of regulatory T cells is a predictor of host immune response and chemotherapy response in colorectal cancer. (Pubmed Central) - Mar 11, 2022
In the GSE72970 cohort, high-Treg CRCs were found to have a 68.8% response to FOLFOX/FOLFIRI without bevacizumab, compared to 44% response in the low-Treg CRCs...We also found that CRCs with higher proportions of Tregs were associated with lower amounts of three microorganisms in the tumor: Lachnoclostridium, flavivirus, and Ornithobacterium. In conclusion, we show that amount of Treg in the tumor is a predictor of host immune response and chemotherapy response in CRC.
- || cisplatin / Generic mfg., irinotecan / Generic mfg.
Review, Journal: Therapeutic Strategies for Patients with Advanced Small Bowel Adenocarcinoma: Current Knowledge and Perspectives. (Pubmed Central) - Mar 11, 2022
Other front-line alternatives are the combination of 5-FU and cisplatin or fluoropyrimidine and irinotecan (FOLFIRI)...To a limited extent, the role of surgical resection for metastatic disease appears to be a valid option, though this approach has not been evaluated in prospective clinical studies. Due to the rareness of the disease, inclusion in clinical trials should be prioritized, and there is hope that targeted therapies and immunotherapy may enter the therapeutic arsenal for these patients.
- || Avastin (bevacizumab) / Roche
P2 data, Journal: Randomized Phase 2 Study Comparing Pathological Responses of Resected Colorectal Cancer Metastases after Bevacizumab with mFOLFOX6 or FOLFIRI (BEV-ONCO Trial). (Pubmed Central) - Mar 11, 2022
Retrospective studies reported that preoperative oxaliplatin-based chemotherapy increased pathological response (PR) in patients resected for colorectal liver metastases (CRLM)...The homogeneity of PR was associated with improved PFS/OS. This trial fails to demonstrate a significant increase in MPRR in patients treated with mFOLFOX6-bevacizumab but confirms PR as an important prognostic factor.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Impact of UGT1A1 Polymorphisms on Febrile Neutropenia in Pancreatic Cancer Patients Receiving FOLFIRINOX: A Single-Center Cohort Study. (Pubmed Central) - Mar 11, 2022
The Cox regression analysis showed that female sex (HR: 2.20; p = 0.031), Eastern Cooperative Oncology Group performance status = 1 (HR: 2.83; p = 0.008), UGT1A1 IM (HR: 4.30; p = 0.004), and UGT1A1 PM (HR: 4.03; p = 0.028) were statistically significant risk factors for FN. We propose that UGT1A1 is the strongest predictive factor for FN and that this gene should be screened prior to the administration of chemotherapy.
- | Avastin (bevacizumab) / Roche
Trial completion, Trial completion date, Metastases: A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 11, 2022
P2, N=264, Completed, Sponsor: Chinese Academy of Medical Sciences
We propose that UGT1A1 is the strongest predictive factor for FN and that this gene should be screened prior to the administration of chemotherapy. Recruiting --> Completed | Trial completion date: Oct 2021 --> Jan 2022
- |||||| Enrollment open: CIRCULATE-US: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (clinicaltrials.gov) - Mar 11, 2022
P2/3, N=1912, Recruiting, Sponsor: NRG Oncology
Recruiting --> Completed | Trial completion date: Oct 2021 --> Jan 2022 Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche
Biomarker, Trial completion date, Trial primary completion date: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Mar 10, 2022
P3, N=3610, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial completion date: Feb 2022 --> Jun 2022 | Trial primary completion date: Feb 2022 --> Jun 2022
- |||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Great plenary presentation by @AGangiMD on SAME protective effects on FOLFOX induced liver injury. @CSCancerCare @DeptSurgeryCS @GenSurg_CS @AGiulianoMD (Twitter) - Mar 10, 2022
- ||||| 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
@AGangiMD educating everyone on SAMe and FOLFOX-associated sinusoidal obstruction syndrome. Nicely presented! #SSO2022 @CedarsSinai @SocSurgOnc @AHPBA @HopSTranCao @sepideh_gholami @drsuswarner @VautheyMD @DanielAnayaMD @IbrahimSahinMD1 @cancerassassin1 @ASCO #MoffittCGSO (Twitter) - Mar 10, 2022
- || carfilzomib / Generic mfg.
Trial completion: Carfilzomib and Hyper-CVAD in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoma (clinicaltrials.gov) - Mar 10, 2022
P1, N=10, Completed, Sponsor: Mehrdad Abedi, MD
Trial completion date: Feb 2022 --> Jun 2022 | Trial primary completion date: Feb 2022 --> Jun 2022 Active, not recruiting --> Completed
- ||| nisevokitug (NIS793) / Novartis
Enrollment change, Trial primary completion date: daNIS-3: Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC (clinicaltrials.gov) - Mar 10, 2022
P2, N=266, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed N=190 --> 266 | Trial primary completion date: Nov 2023 --> Jan 2025
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical, Journal, HEOR: Cost-Effectiveness of First-Line Cetuximab in Metastatic Colorectal Cancer in Saudi Arabia. (Pubmed Central) - Mar 9, 2022
N=190 --> 266 | Trial primary completion date: Nov 2023 --> Jan 2025 FOLFIRI plus cetuximab is cost-effective compared with FOLFIRI plus bevacizumab or FOLFIRI alone in RAS wild-type left-sided mCRC and patients who undergo resection.
- | Tuoyi (toripalimab) / Shanghai Junshi Biosci, Coherus Biosci
Retrospective data, Journal: Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma. (Pubmed Central) - Mar 9, 2022
In the propensity score-matched cohorts (47 pairs), the outcomes in the TorHAIC group were also better than those in the lenvatinib group (p < .05). Toripalimab plus HAIC was tolerable and effective in advanced HCC and the result needs to be confirmed in the phase III trial.
- | paclitaxel / Generic mfg., irinotecan / Generic mfg.
Retrospective data, Journal: Beyond Front-Line Therapy for Unresectable Gastroesophageal Adenocarcinoma: Are There Differences in Subsequent Therapy Sequencing? (Pubmed Central) - Mar 9, 2022
Toripalimab plus HAIC was tolerable and effective in advanced HCC and the result needs to be confirmed in the phase III trial. Our study, examining a practical issue of how to sequence second- and third-line therapies, documents that one sequence versus the other does not compromise patient outcomes and overall, our patients had an outstanding OS of beyond 19 months when they receive third-line therapy.
- || 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Retrospective data, Review, Journal: Chemotherapy in pancreatic ductal adenocarcinoma: When cytoreduction is the aim. A systematic review and meta-analysis. (Pubmed Central) - Mar 9, 2022
Our meta-analysis did not find significant superiority of one regimen over the other in terms of RECIST-based cytoreduction both in palliative and curative setting of patients with pancreatic adenocarcinoma. The significantly better DCR with FOLFIRINOX compared with GEM-NAB deserves further investigation including waterfall plot and correlations with potential predictive factors.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Observational data, Journal, Residual disease, Minimal residual disease: Improvement in the Neutrophil-Lymphocyte Ratio after Combined Fluorouracil, Leucovorina and Oxaliplatino based (FOLFOX) Chemotherapy for Stage III Colon Cancer is Associated with Improved Minimal Residual Disease and Outcome. (Pubmed Central) - Mar 9, 2022
The significantly better DCR with FOLFIRINOX compared with GEM-NAB deserves further investigation including waterfall plot and correlations with potential predictive factors. Immune function as measured by the NLR is associated with MRD prognostic subtypes, improvements in the NLR are associated with improvements in MRD post chemotherapy but neither baseline NLR or MRD predicted outcome.
- Vectibix (panitumumab) / Amgen, Takeda
Age-related disparity in treatment outcome and adverse events among patients with metastatic colorectal cancer (mCRC) (E-Poster Website) - Mar 9, 2022 - Abstract #AACR2022AACR_7535;
P3
Patients with early-onset mCRC had not only worse OS in both treatment arms but also higher incidence of adverse events. Our management approach should adapt to the unique features of this patient population.
- PD-1 blockades plus targeted therapy and cytotoxic drugs as conversion therapy in unresectable metastatic colorectal cancer (mCRC): A real-world experience (E-Poster Website) - Mar 9, 2022 - Abstract #AACR2022AACR_7056;
The triplet regimen of anti-PD-1, bevacizumab or cetuximab and chemotherapy was safe and tolerant and showed encouraging anti-tumor activities in MSS mCRC. Our experience suggested the clinical value of PD-1 blockades as initial treatment in MSS mCRC.
- 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Evaluation of AS-10, identified based on SAR studies of newly generated organoselenium compounds, as a potential colorectal cancer therapeutic acting potentially by acetylating histones (E-Poster Website) - Mar 9, 2022 - Abstract #AACR2022AACR_6964;
Moreover, AS-10 was assessed for its ability to act as an acetyl donor for histone acetyltransferase (HAT) and was found to initiate HAT activity in the absence of Acetyl-CoA in pancreatic epithelioid carcinoma (Panc-1) and colorectal carcinoma (HCT116) cells. In conclusion, AS-10 was identified as the best among the 24 analogs, in vitro and in vivo, when treating CRC and found to be capable of inducing HAT activity in both pancreatic and colorectal carcinoma elucidating a possible mechanism of action.
- BOLD-100 / Intezyne, Bold Therap
Utilization of cancer cell line screening and bioinformatic analyses to identify optimal developmental pathways for the novel anticancer agent BOLD-100 (E-Poster Website) - Mar 9, 2022 - Abstract #AACR2022AACR_6948;
Utilizing bladder cancer as a case study, subsequent combination testing of BOLD-100 in combination with fluorouracil or cisplatin demonstrated that BOLD-100 enhanced cell death across different bladder cancer cell lines through synergistic interactions with these standard-of-care agents...Collectively, BOLD-100 showed a unique sensitivity profile across a panel of over 300 cancer cell lines, identifying multiple potential indications for future development. Subsequent investigations into several cancer types of interest and drug combinations are ongoing.
- 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Tumor heterogeneity in response to therapy and its association with outcome in patients with metastatic colorectal cancer (mCRC) (E-Poster Website) - Mar 9, 2022 - Abstract #AACR2022AACR_6654;
P3
Higher tumor heterogeneity in response to chemotherapy within an individual patient was independently associated with early disease progression and shorter survival. It could provide prognostic value complementary to existing tumor heterogeneity variables in patients with mCRC.
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancer (E-Poster Website) - Mar 9, 2022 - Abstract #AACR2022AACR_6584;
HGF induced cetuximab resistance by AKT and ERK activation while capmatinib, a MET inhibitor, significantly increased the anti-tumor effects of cetuximab in the presence of HGF in vitro. Our data may provide evidence of future clinical trials of dual EGFR and MET targeting strategies in patients with HGF-high, RAS/RAF wild-type mCRC.
- Folic acid combined chemotherapy has an immediate effect on C1 methionine cycle and consequential DNA methylation in liquid biopsy samples of colorectal cancer patients (Section 7) - Mar 9, 2022 - Abstract #AACR2022AACR_6162;
In each patient, the HCY level of plasma was decreased by an average of 17% after oxaliplatin treatment with the combination of capecitabine (XELOX) and also with 5-FU + leucovorin (FOLFOX) agents...The methionine cycle is responsible for the DNA methylation maintenance, and though the amount of members of this pathway was reduced, only a moderately increased DNA methylation could be detected even in such a short period time. Co-administration of high dose leucovorin as a folate derivative and a methyl donor with further chemotherapeutic agents may actively contribute to genome alterations.
- 5-fluorouracil / Generic mfg.
The polymeric fluoropyrimidine CF10 overcomes limitations of 5-FU in pancreatic ductal adenocarcinoma cells through increased replication stress (Section 22) - Mar 9, 2022 - Abstract #AACR2022AACR_6024;
FOLFIRINOX is the drug regimen of choice, one component of which is 5-Fluorouracil (5-FU) which causes serious gastrointestinal and hematopoietic toxicities and is vulnerable to resistance due, in part, to thymidylate synthase (TS) overexpression...Further, we find that the activity of CF10, but not 5-FU can be enhanced through combination with inhibitors of ATR and Wee1 that regulate the S and G2 damage checkpoints. Our results indicate CF10 has potential to supersede the established benefit of 5-FU in PDA treatment and indicate novel combination approaches that may be beneficial compared to well-established regimens used currently for 5-FU.